FindTrial
Sign In

Dose related effect of Extracorporeal Shock wave therapy for chronic plantar fasciitis between fix and titrate dose: Randomized controlled trial

Dose related effect of Extracorporeal Shock wave therapy for chronic plantar fasciitis between fix and titrate dose: Randomized controlled trial

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20200505006
Enrollment
Unknown
Registered
2020-05-05
Start date
2020-05-15
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

No exactly method and energy density reflux of ESWT for chronic Plantar fasciitis Plantar fasciitis Extracorporeal shockwave therapy : ESWT Dose efficacy

Interventions

Extracorporeal shockwave therapy (ESWT) ESWT DUOLITH® SD1 T&#45
TOP »F&#45
SW ultra« with focused »SEPIA •fix dose : 1&#44
000 shocks/session&#44
Energy flux density 0.16 mJ/mm2 weekly * total 3 sessions ,Extracorporeal shockwave therapy (ESWT) ESWT DUOLITH® SD1 T&#45
SW ultra« with focused »SEPIA • titrate dose : 1&#44
Energy flux density 0.16 mJ/mm2 Evaluated pain and adjust every 200 shocks(pain as tolerate &#44
VAS < 3) by increase or decrease 0.01 mJ/time Minimum dose 0.08 mJ/mm2 &#44
maximum dose 0.28 mJ/mm2 weekly * total 3 sessions
Experimental Procedure/Surgery,Active Comparator Procedure/Surgery
Titrate dose,Fix dose

Sponsors

No
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.age 18 &#45; 60 years old 2.Diagnosed by orthopedist : pain at medial foot when start walking and tender at medial calcalneal tuberosity and symptoms more than 3 months

Exclusion criteria

Exclusion criteria: 1. brain and recognitive impairment 2. Body Mass Index morethan 30 kg/m2 3. Visual Analog Scale (VAS) lessthan 2 4. recieve steriod injection or shockwave within 3 month 5. history of calcaneal fracture or foot and ankle surgery 6. systemic disorders: infection&#44; Gout &#44;Rheumatoids&#44;bone tumor 7. pregnancy 8. on pacemaker 9. Bleeding disorder: Hemophilia

Design outcomes

Primary

MeasureTime frame
pain Visual analog score pre and post intervention and between group week 1&#44;2&#44;3 and month 3&#44;6 Numeric rating scale: NRS)—

Secondary

MeasureTime frame
functional score pre and post intervention and between group week 1&#44;2&#44;3 and month 3&#44;6 Visual Analogue Scale foot and ankle : VAS FA—

Countries

Thailand

Contacts

Public ContactKorakot Maliwankul

Orthopedic department &#44;Prince of Songkhla University

Koopy_medy@hotmail.com094-5518428

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026